

Made in Europe - assessing the feasibility of reshoring active pharmaceutical ingredient (API) production to Europe

Verena Knoll, Caroline Steigenberger, Stefan Fischer, Sabine Vogler
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies,
Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG /
Austrian National Public Health Institute), Vienna, Austria
✉ verena.knoll@goeg.at

Reshoring as a potential solution to prevent medicine shortages

BACKGROUND

- Reasons for medicine shortages in Europe are **complex** and **multi-factorial**.
- One influencing aspect: the **availability of APIs** for medicines
- High dependency** on Asia for certain APIs as many production sites are located there due to lower cost
- Reshoring API production – meaning the **relocation of production** back to Europe - as a potential solution to prevent medicine shortages

OBJECTIVE

- To explore the **key enablers and barriers** that impact reshoring of API production to Europe and to identify **prerequisites** for successful reshoring processes

METHODOLOGY



Targeted literature review

- Based on a study conducted for the European Parliament
- Peer-reviewed and grey literature
- Focus: global

Stakeholder-consultation due to inconclusive results




Focus group interviews

- With key stakeholders from policy-making, industry and research
- Focus: national
- Stakeholders from Austria, Spain, France
- Analyzed through a qualitative content analysis

Methodological triangulation

Assessing four pillars of feasibility for reshoring API production

PRELIMINARY FINDINGS



Is reshoring API production to European countries feasible?

CONCLUSIONS BASED ON PRELIMINARY FINDINGS

- Reshoring API production to Europe is considered realistic by stakeholders in France and Spain, Austrian stakeholders were more hesitant regarding its feasibility.
- Strengthening local production of APIs is generally seen as a high priority by all stakeholder groups
- First step: incentivizing and encouraging local production through changes in pricing and procurement of medicines
- A European solution and stronger cooperation between industry and policy-makers are essential

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), 1010 Vienna, Austria, ppri.goeg.at & www.goeg.at

This study was partially funded by the European Parliament.

5th PPRI Conference
Vienna, 25–26 April 2024



Gesundheit Österreich
GmbH